NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

IBRX

ImmunityBio Inc

Jul 01 • 09:54AM ET

2.60

Dollar change -0.04
Percentage change -1.50	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX PFE VRTX REGN GILD ALNY AMGN BIIB

| Held by: VTI IWM VB XBI VBK VXF IWO SCHA VTWO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.58	Insider Own	89.60%	Shs Outstand	853.39M	Perf Week	-6.80%
Market Cap	2.30B	Forward P/E	-	EPS next Y	-0.29	Insider Trans	0.00%	Shs Float	91.82M	Perf Month	-2.24%
Enterprise Value	3.06B	PEG	-	EPS next Q	-0.11	Inst Own	9.08%	Short Float	78.80%	Perf Quarter	-13.61%
Income	-409.10M	P/S	73.51	EPS this Y	23.85%	Inst Trans	53.68%	Short Ratio	7.80	Perf Half Y	-3.33%
Sales	31.22M	P/B	-	EPS next Y	37.73%	ROA	-116.15%	Short Interest	72.36M	Perf YTD	1.57%
Book/sh	-0.69	P/C	37.26	EPS next 5Y	-	ROE	-	52W High	7.48 -65.24%	Perf Year	-60.24%
Cash/sh	0.07	P/FCF	-	EPS past 3/5Y	11.44% 2.39%	ROIC	-182.90%	52W Low	1.83 42.09%	Perf 3Y	-37.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	150.86% 221.39%	Gross Margin	45.92%	Volatility	4.82% 7.33%	Perf 5Y	-78.58%
Dividend TTM	-	EV/Sales	97.92	EPS Y/Y TTM	47.67%	Oper. Margin	-1003.83%	ATR (14)	0.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.05	Sales Y/Y TTM	10238.41%	Profit Margin	-1310.30%	RSI (14)	41.20	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.22	EPS Q/Q	23.73%	SMA20	-11.39%	Beta	-0.02	Target Price	11.40
Payout	-	Debt/Eq	-	Sales Q/Q	41192.50%	SMA50	-3.01%	Rel Volume	0.41	Prev Close	2.64
Employees	680	LT Debt/Eq	-	Earnings	May 12 BMO	SMA200	-21.70%	Avg Volume	9.28M	Price	2.60
IPO	Jul 28, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.19% 3.39%	Trades		Volume	417,250	Change	-1.50%

Date	Action	Analyst	Rating Change	Price Target Change
May-20-25	Upgrade	Piper Sandler	Neutral → Overweight	$5
Mar-06-25	Initiated	H.C. Wainwright	Buy	$8
Jan-10-25	Initiated	BTIG Research	Buy	$6
May-12-23	Downgrade	Piper Sandler	Overweight → Neutral	$10 → $4
Aug-03-22	Initiated	Jefferies	Buy	$8

Jun-24-25 03:51PM	ImmunityBio (IBRX) Attains FDA's Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA (Insider Monkey)
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire)
Jun-04-25 11:56PM	Why ImmunityBio, Inc. (IBRX) Skyrocketed Today (Insider Monkey) +8.12%
Jun-03-25 09:25AM	ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield (TipRanks)
08:45AM	ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer (Business Wire)
09:00AM	Loading…
Jun-02-25 09:00AM	ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA, the Cancer BioShield Platform, in Patients With Solid Tumors (Business Wire)
May-27-25 08:00AM	ImmunityBio, Saudi Arabias Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield Platform in the Middle East (Business Wire)
May-22-25 08:46AM	CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success (Zacks)
06:00AM	Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT (Insider Monkey)
May-21-25 08:31PM	Why ImmunityBio, Inc. (IBRX) Crashed Today (Insider Monkey) -8.62%
May-20-25 08:59PM	Jim Cramer Notes ImmunityBio (IBRX) Has "Been Losing Money Forever" (Insider Monkey)
12:43PM	Why ImmunityBio, Inc. (IBRX) Surged Last Week (Insider Monkey)
May-19-25 08:30PM	Lightning Round: Zoom is doing a lot right, but it's taking them a really long time, says Jim Cramer (CNBC TV)
May-15-25 12:00PM	ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade (Zacks) +7.23%
May-12-25 11:12PM	Why ImmunityBio, Inc. (IBRX) Soared Today (Insider Monkey) +14.01% +6.36%
07:35AM	Loading…
07:35AM	ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code (Business Wire)
May-09-25 08:30AM	Is ImmunityBio, Inc. (IBRX) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-06-25 10:00AM	Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
May-05-25 05:05PM	ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA (Seeking Alpha) -17.32%
06:30AM	ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agencys Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025 (Business Wire)
May-01-25 10:01AM	ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-29-25 12:50PM	ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish (Seeking Alpha) -5.32%
Apr-28-25 08:30AM	Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone Best in Disease and Best in Class with 5 Year Follow-Up (Business Wire)
Apr-21-25 04:21PM	ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting (Business Wire) +7.17%
Apr-17-25 12:05AM	Why ImmunityBio, Inc. (IBRX) Declined on Wednesday (Insider Monkey)
Apr-15-25 08:00AM	ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA to Treat Lymphopenia (Business Wire)
12:40AM	Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? (Insider Monkey)
Apr-09-25 09:42AM	ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple (Insider Monkey) +7.44%
06:16AM	Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? (Insider Monkey)
07:30AM	Loading…
Apr-08-25 07:30AM	ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor (Business Wire) -11.03%
Apr-07-25 05:00AM	ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch (Business Wire)
Apr-03-25 05:54PM	ImmunityBio: Taking Care Of Business (Seeking Alpha)
Mar-29-25 10:39PM	Why ImmunityBio Inc. (IBRX) Went Up Last Week? (Insider Monkey)
Mar-26-25 06:00AM	ImmunityBio to Host Investor Day (Business Wire)
Mar-25-25 05:41PM	Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket? (InsiderMonkey)
Mar-13-25 09:00AM	ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching (Business Wire)
Mar-03-25 07:30AM	ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024 (Business Wire) -13.37%
Mar-01-25 04:09PM	Why ImmunityBio, Inc. (IBRX) Soared on Friday (Insider Monkey)
Feb-27-25 07:10PM	ImmunityBio Receives FDA RMAT Designation for ANKTIVA and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer (Business Wire) +15.03%
Feb-20-25 12:00PM	Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz (TipRanks) -6.67%
Feb-19-25 09:00AM	FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE BCG Shortage (Business Wire) +16.42%
Feb-13-25 03:05PM	ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ (Business Wire)
Jan-29-25 08:30AM	ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer (Business Wire)
Jan-27-25 09:00AM	ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ (Business Wire)
Jan-19-25 12:54PM	Why ImmunityBio, Inc. (IBRX) Dominated Last Week's Rally (Insider Monkey)
Jan-18-25 03:51PM	Why Did Immunitybio (IBRX) Go Down on Friday? (Insider Monkey)
Jan-16-25 07:19PM	Why ImmunityBio, Inc. (IBRX) Is Skyrocketing (Insider Monkey) +27.20%
Jan-15-25 05:20PM	ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom (Business Wire)
05:20PM	ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency (Business Wire)
Jan-13-25 04:33PM	Why ImmunityBio, Inc. (IBRX) Is the Top Small Cap Stock to Buy with the Highest Upside Potential (Insider Monkey) -6.45%
Jan-06-25 09:00AM	ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA Is Now Effective (Business Wire)
Dec-12-24 08:00AM	D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering (GlobeNewswire)
Dec-11-24 07:30AM	ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock (Business Wire) -32.11%
Dec-10-24 04:24PM	ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-23-24 10:24AM	Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-21-24 10:00AM	ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment (PR Newswire)
Nov-19-24 08:00AM	ImmunityBio Completes ANKTIVAs Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months (Business Wire) +6.79%
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)
Nov-12-24 07:15AM	ImmunityBio Reports Third-Quarter 2024 Financial Results (Business Wire) -9.17%
Oct-25-24 03:22PM	ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock? (GuruFocus.com) +26.37%
Oct-24-24 09:00AM	First Patients Dosed in Phase 1 Clinical Study of ImmunityBios CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma (Business Wire) +21.68%
Oct-21-24 09:00AM	ImmunityBio to Participate in the Jefferies London Healthcare Conference (Business Wire)
Sep-09-24 08:30AM	ImmunityBio Presents Positive Long-Term Overall Survival Datain Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA and Checkpoint Immunotherapyat WorldConferenceonLungCancer (Business Wire) +5.03%
Aug-12-24 08:46AM	ImmunityBio's ANKTIVA Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval (Business Wire)
Aug-06-24 09:00AM	ImmunityBio Announces Study of ANKTIVA in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer (Business Wire)
Jul-01-24 03:26AM	Notice to Long-Term Shareholders of ImmunityBio, Inc. (IBRX): Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile)
Jun-26-24 09:41AM	ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why (Zacks) -6.88%
Jun-20-24 09:00AM	ImmunityBio Announces Insurance Coverage of ANKTIVA Across Multiple States with First Commercial Doses Administered Just Weeks After FDA ApprovalOpening New Era for Immunotherapy Beyond Checkpoint Inhibitors (Business Wire)
06:15AM	3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions (InvestorPlace)
Jun-07-24 09:13AM	ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update (Business Wire)
May-17-24 09:00AM	Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast (Business Wire)
May-10-24 09:53AM	IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
May-09-24 06:01AM	The 3 Best Bargain Stocks to Buy in May 2024 (InvestorPlace)
May-07-24 08:00AM	ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA (Business Wire) +5.76%
May-06-24 06:00AM	Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells (InvestorPlace) -14.64%
May-02-24 04:04PM	ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types (Business Wire) +5.04%
May-01-24 10:05AM	Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 (PR Newswire) +6.88%
Apr-30-24 08:00AM	ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA Approval in Fireside Chat at the Annual Conference of the American Urological Association (Business Wire) -11.12%
Apr-25-24 12:03AM	ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer (Business Wire) +6.02%
Apr-23-24 04:55PM	ImmunityBio's bladder cancer therapy wins FDA approval (Yahoo Finance Video) +11.13% -12.20%
Apr-22-24 09:56PM	ImmunityBio Announces FDA Approval of ANKTIVA, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (Business Wire) -6.26%
Apr-19-24 11:02AM	12 Most Shorted Stocks in 2024 (Insider Monkey) +7.33%
Mar-19-24 09:53PM	IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +10.31%
Mar-14-24 08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire)
Mar-06-24 09:00AM	NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy (Business Wire) +5.39%
Mar-05-24 09:00AM	N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study (Business Wire)
Feb-21-24 09:00AM	ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial (Business Wire)
Feb-05-24 09:00AM	ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG (Business Wire)
Jan-02-24 07:10AM	ImmunityBio inoculates itself against financial pain, inking $210M royalty deal to get cancer drug to market (FierceBiotech.com)
06:00AM	ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million (Business Wire)
Nov-16-23 09:00AM	ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-07-23 09:00AM	First Data for ImmunityBios Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity (Business Wire)
Oct-26-23 09:00AM	FDA Accepts ImmunityBios BLA Resubmission as Complete and Sets New PDUFA Date (Business Wire) +29.75%
Oct-23-23 09:00AM	ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ (Business Wire) +10.00%
Oct-09-23 08:45AM	Lawsuit Notice: Investors who lost money with ImmunityBio, Inc. (NASDAQ: IBRX) shares should contact the Shareholders Foundation (GlobeNewswire)
Sep-11-23 06:00AM	ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities (Business Wire) +19.38%
Aug-03-23 09:00AM	ImmunityBio Names Enrique Diloné as Chief Technology Officer (Business Wire) +9.02%
Jul-20-23 08:32PM	ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors (Business Wire) -6.77%
Jul-10-23 09:30AM	Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients (Business Wire)

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LAUER REGAN J	Chief Accounting Officer	Feb 22 '25	Option Exercise	0.00	4,065	0	111,927	Feb 25 09:11 PM
SOON-SHIONG PATRICK	See remarks	Feb 22 '25	Option Exercise	0.00	114,329	0	29,588,261	Feb 25 09:11 PM
Sachs David C.	Chief Financial Officer	Feb 22 '25	Option Exercise	0.00	40,650	0	241,480	Feb 25 09:11 PM
Adcock Richard	CEO & President	Feb 22 '25	Option Exercise	0.00	152,439	0	412,585	Feb 25 09:11 PM
Simon Barry J.	Director	Feb 22 '25	Option Exercise	0.00	15,243	0	3,249,024	Feb 25 09:11 PM
Simon Barry J.	Director	Jan 22 '25	Option Exercise	2.00	110,020	219,864	3,233,781	Jan 24 08:47 PM
Adcock Richard	CEO & President	Dec 31 '24	Option Exercise	0.00	34,483	0	277,621	Jan 03 04:54 PM
Sachs David C.	Chief Financial Officer	Dec 31 '24	Option Exercise	0.00	30,397	0	216,235	Jan 03 04:54 PM
LAUER REGAN J	Chief Accounting Officer	Dec 15 '24	Option Exercise	0.00	21,031	0	115,365	Dec 16 07:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IBRX

ImmunityBio Inc

Upgrade your FINVIZ experience